Endologix has acquired the Pounce mechanical thrombectomy system from Surmodics to expand its vascular intervention portfolio and support procedural advancements in thrombi removal.
The Pounce system will remain marketed under its existing US Food and Drug Administration (FDA) clearance through the transition period.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is designed for the non-surgical removal of thrombi and emboli from peripheral arteries.
The system uses dual-basket technology and a nitinol collection funnel, eliminating the need for capital equipment, thrombolytics, or aspiration.
This platform includes several commercially available configurations: Pounce LP, Pounce, and Pounce XL, enabling clinical use across a wide array of peripheral arterial vessel sizes, including smaller and more distal vessels.
Endologix president and CEO John Liddicoat said: “The Pounce thrombectomy system is a strong strategic and clinical fit for Endologix. It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio.
“We are excited to welcome members of the Pounce team as part of our intentional investment in innovation that helps vascular specialists deliver better care.”
The acquisition expands Endologix’s commercial vascular device options for clinical partners who already utilise its Detour, Alto, and AFX2 platforms.
By integrating the Pounce system, the company will offer a wider continuum of care for peripheral vascular disease.
As part of the transaction, a core group of Surmodics team members supporting Pounce will join Endologix.
Endologix’s product portfolio spans development and commercial-stage therapies for vascular conditions, and it is wholly owned by Deerfield Management.
In November 2024, Endologix reported the 36-month outcomes of a study that evaluated its DETOUR System for treating complex peripheral arterial disease (PAD).
